Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis

Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo

(2014) R Sonntag et al.   Cell Death & Disease

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

RIP3: a molecular switch for necrosis and inflammation

(2013) K. Moriwaki et al.   GENES & DEVELOPMENT

Sorafenib in patients with refractory or recurrent multiple myeloma

(2013) Anna Yordanova et al.   HEMATOLOGICAL ONCOLOGY

Direct Interaction of Bax and Bak Proteins with Bcl-2 Homology Domain 3 (BH3)-only Proteins in Living Cells Revealed by Fluorescence Complementation

(2013) Laura Vela et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

(2012) P. L. Bergsagel et al.   BLOOD

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model

(2012) P. Kharaziha et al.   CANCER RESEARCH

Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth

(2012) C Dudgeon et al.   ONCOGENE

The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs

(2011) Tencho Tenev et al.   MOLECULAR CELL

Ripped to death

(2011) Ricardo Weinlich et al.   TRENDS IN CELL BIOLOGY

Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells

(2010) Nuria López-Royuela et al.   BIOCHEMICAL PHARMACOLOGY

Sorafenib

(2009) Gillian M. Keating et al.   DRUGS

PUMA, a potent killer with or without p53

(2009) J Yu et al.   ONCOGENE

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

(2009) V Ramakrishnan et al.   ONCOGENE

Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis

(2008) Patricia Balsas et al.   BIOCHEMICAL PHARMACOLOGY

Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling

(2008) G. Roue et al.   CLINICAL CANCER RESEARCH

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway

(2008) W Zhang et al.   LEUKEMIA